Novavax, Inc. (LON:0A3S)

Market Cap	809.20M
Revenue (ttm)	792.04M
Net Income (ttm)	254.24M
Shares Out	n/a
EPS (ttm)	1.54
PE Ratio	3.18
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	84,601
Average Volume	31,654
Open	6.67
Previous Close	6.67
Day's Range	6.68 - 6.85
52-Week Range	5.02 - 11.78
Beta	2.31
RSI	44.93
Earnings Date	Feb 26, 2026

About Novavax

Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adoles...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1987
• Employees: 952
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A3S

Financial Performance

In 2024, Novavax's revenue was $682.16 million, a decrease of -30.65% compared to the previous year's $983.71 million. Losses were -$187.50 million, -65.60% less than in 2023.

Financial numbers in USD